Reduction of inflammation and fibrosis in NASH model

Non-alcoholic steatohepatitis (NASH) is a type of fatty liver disease (FLD) and can lead to cirrhosis and liver cancer. Our tests showed that the GLP-1/glucagon co-agonist can help reduce fat accumulation in the liver, leading to notable reductions in inflammation and fibrosis in a preclinical model of NASH.

-----------------------------------------------------------------------
Global site: https://www.astrazeneca.com/
Careers site: https://careers.astrazeneca.com/

Follow us:
Twitter: https://twitter.com/AstraZeneca
LinkedIn: https://www.linkedin.com/company/astrazeneca/
Instagram: https://www.instagram.com/astrazeneca/
Facebook: https://www.facebook.com/astrazenecacareers/

NASHsteatohepatitisfatty liver disease